Tuesday, September 1, 2026

How We Source Explore Search

Via News Knowledge File

AstraZeneca AB

organization80% conf.·synced Aug 13, 2026

Pharmaceutical company with license agreement with Insmed

57

sourced metrics

409

relationships

20

stated objectives

8

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Revenue

30595USD

Jul 27, 2026source

Eps

1.61USD

Jul 27, 2026source

Dividend Per Share

1.06USD

Jul 27, 2026source

Stock Price

168.90USD

Jul 17, 2026source

Stock Return 30day

5.2percent

Apr 1, 2026source

Stock Return 1year

54.8percent

Apr 1, 2026source

Free Cash Flow

9.49USD

Apr 1, 2026source

Stock Return Ytd

12.1percent

Apr 1, 2026source

Projected Free Cash Flow

20.16USD

Apr 1, 2026source

Valuation Score

3out_of_6

Apr 1, 2026source

Intrinsic Value Dcf

238.68USD

Apr 1, 2026source

Stock Return 7day

-0.6percent

Apr 1, 2026source

Marathon Holding Value

12.85USD

Mar 31, 2026source

Marathon Holding Pct Aum

2.9percent

Mar 31, 2026source

Return 1year

21.8percent

Mar 1, 2026source

Analyst Price Target

165.33GBP

Mar 1, 2026source

Free Cash Flow Projected

20.2USD

Mar 1, 2026source

Intrinsic Value Per Share

242.86GBP

Mar 1, 2026source

Stated objectives

Reach $80bn in annual sales by 2030

target: 80 billion USD by 2030-01-01 00:00:00stated

Achieve operating margin in mid-thirties percent range

target: 35 percent stated

High single digit revenue growth for 2025 on constant currency basis

target: 7-9 percent by 2025-01-01 00:00:00stated

Low double digit growth in adjusted earnings per share for 2025 on constant currency basis

target: 10-12 percent by 2025-01-01 00:00:00stated

Increase total revenue by mid-to-high single-digit percentage for FY 2026 at constant exchange rates

target: mid-to-high single-digit percentage growth by 2026-12-31 00:00:00stated

Increase core EPS by low double-digit percentage for FY 2026 at constant exchange rates

target: low double-digit percentage growth by 2026-12-31 00:00:00stated

Invest $15 billion in China through 2030 to expand medicines manufacturing and R&D

target: $15 billion by 2030-12-31 00:00:00stated

Complete more than 20 Phase 3 trial readouts in 2026

target: 20+ Phase 3 readouts by 2026-12-31 00:00:00stated

Obtain FDA approval for baxdrostat as first-in-class aldosterone synthase inhibitor for hard-to-control hypertension

target: regulatory approval stated

Advance portfolio of medicines for organ protection by slowing or stopping disease progression, paving way towards regenerative therapies in CVRM

stated

Relationship graph · 409 connections

Developed by

145

Competes with

73

Employs

25

Partnered with

21

located in

13

headquartered in

12

contracted by

10

acquired by

10

Via News coverage

Methes Energies International Ltd And IRobot On The List Of Winners And Losers Of Friday's US Session

Niu Technologies And Tilray On The List Of Winners And Losers Of Tuesday's US Session

Hostess Brands And SRAX On The List Of Winners And Losers Of Tuesday's US Session

Celcuity And CohBar On The List Of Winners And Losers Of Friday's US Session

BioCardia And AGM Group Holdings On The List Of Winners And Losers Of Thursday's US Session

Viking Therapeutics And Speed Commerce On The List Of Winners And Losers Of Tuesday's US Session

FibroGen Stock Bullish Momentum With A 10.53% Rise On Tuesday

VerifyMe And Hycroft Mining Holding Corporation On The List Of Winners And Losers Of Tuesday's US Session

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

AI Capital Surge: Late-August 2026 Funding Wave Spans Fintech, Enterprise Agents, and Robotics

A dense cluster of funding rounds landing on 2026-08-28 — from identity/fraud fintech player Socure ($156M plus its acquisition of Fravity) to enterprise AI agent startups (Instinct, Generalist AI, Owner), model infrastructure (Stability AI, Emerald AI), and autonomous logistics/aerospace (Gatik, Regent Craft) — signals investors are rotating aggressively into AI-native companies with demonstrable ROI, especially in financial risk/compliance and back-office automation. Parallel signals (Multiverse Computing's compression benchmarks cutting inference cost/latency, and Arkestro/CloneOps.ai publishing hard savings and labor-displacement figures) suggest the funding is chasing efficiency and measurable economic impact rather than pure model scale.

Our read on the data ›

Signals we're tracking

Satellite-Terrestrial Network Integration Acceleration

Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,980

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,980 facts checked against source5,267 source documents archived

Query this data → isubstrate.com